gastric cancer
Conditions
Interventions
Experimental group:D2 radical surgery +HIPEC twice + systemic chemotherapy 8 cycles
The control group:D2 radical surgery +systemic chemotherapy 8 cycles
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed patients did not receive chemotherapy or radiotherapy before the clinical trial; 2. Pathological diagnosis of gastric adenocarcinoma; 3. Patients with advanced stage T(4), N(0-3), M0 (ENDOSCOPIC ultrasound or CT) (AJCC, 7th edition, 2010); 4. Male or non-pregnant female; 5. Aged between 18 and 75 years; 6. Before enrollment, hemodynamic indexes (including blood count, liver and kidney function) were normal. For example, WBC > 3.5 x 10^9/L, neutrophils > 1.5 x 10^9/L, platelets > 100 x 10^9/L, bilirubin < 1.5 times the upper limit of normal, glutamic-oxalacetic transaminase and glutamic-pyruvic transaminase creatinine < 2 times the upper limit of normal, serum creatinine < 1.2mg/d; 7. Cardiac function was good before enrollment, no myocardial infarction occurred within half a year, hypertension and other coronary heart diseases were well controlled, and no other uncontrollable benign diseases; 8. ECOG: 0-1; 9. Did not participate in other research projects before and during treatment; 10. Informed consent of the patient has been obtained.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors within 5 years; 2. Patients with peritoneal metastasis; 3. Other serious diseases that are difficult to control at the same time (including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction below 50%, serious liver disease, kidney disease, infectious disease or uncontrolled diabetes or hypertension, etc.); 4. Received anticancer drugs in other clinical trials; 5. Failure to comply or inability to complete the entire trial treatment; 6. Extensive adhesions in the abdominal cavity; 7. Para-aortic lymph nodes or retropancreatic lymph nodes metastases; 8. Refusal to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 3-year and 5-year survival rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| The progression-free survival rate;The recurrence rate;The safety of the treatment; | — |
Countries
China
Contacts
Public ContactDu Yian
Zhejiang Cancer Hospital
Outcome results
None listed